Inotiv, Inc. (NOTV)

In the past six months, Inotiv's stock price has significantly declined. Key events include a cybersecurity incident in February 2026, which led to a slight increase in stock price, and the release of First Quarter Financial Results for Fiscal 2026, which resulted in a decrease in stock price due to a widening net loss. Inotiv also announced leveraging LifeNet Health's platform and partnered with VUGENE, both leading to decreases in stock price. The company reported its Fourth Quarter and Full Year Financial Results for Fiscal 2025, which also saw a decrease in stock price. Inotiv received multiple short-term waivers on its minimum liquidity covenant from lenders, indicating ongoing financial challenges.

While specific seasonal patterns are not extensively outlined, Inotiv's CEO has indicated that the holiday season can introduce seasonality related to revenue recognition. The company is committed to building a recurring client base and is aware of demand fluctuations. The company's services may experience demand influenced by research cycles, funding availability, and the pipeline of pharmaceutical and medical device companies.

Inotiv, Inc. is a contract research organization specializing in nonclinical and analytical drug discovery and development services. The company operates in the Healthcare sector, focusing on Diagnostics & Research and Life Sciences Tools and Services. Inotiv's business is divided into two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment offers services like safety assessment, toxicology, and regulatory compliance testing, while the RMS segment focuses on the production and sale of research models and related products. Inotiv aims to assist clients in advancing therapies by offering services from early-stage discovery through preclinical development.

Inotiv has a global presence with over 2,000 employees across more than 22 locations in North America and Europe. In North America, its DSA segment services are delivered from locations in West Lafayette, IN; Evansville, IN; Fort Collins, CO; Boulder, CO; St. Louis, MO; and Gaithersburg, MD. The RMS operations in North America are situated in Indianapolis, IN; Livermore, CA; St. Louis, MO; Alice, TX; Cumberland, VA; Dublin, VA; Frederick, MD; Denver, PA; and Madison, WI. In Europe, the company's RMS operations are located in Hillcrest, Huntingdon, and Blackthorn in the United Kingdom, Horst in the Netherlands, Gannat in France, and Desio in Italy. The company's principal executive offices are located in West Lafayette, Indiana.

In the past year, Inotiv's brand reputation has been influenced by both positive achievements and challenges. The cybersecurity incident in February 2026 negatively affected the company's reputation regarding data security. Strategic partnerships with VUGENE and LifeNet Health enhanced the company's reputation as an innovator. Inotiv was ranked 182nd on the 2025 Deloitte Technology Fast 500, highlighting its revenue growth and successful strategy. The company's stock price decline and the need for multiple short-term waivers on its credit agreement liquidity covenants could raise concerns among investors.

Inotiv has a diverse ownership structure including institutional investors, insiders, and public/individual shareholders. Major institutional owners include Balyasny Asset Management Llc, Vanguard Group Inc, and BlackRock, Inc. Insider ownership is also significant, with key individual insider shareholders including Andrew H Baker and Robert Jr. Leasure. Public companies and individual investors hold a substantial portion of the company.